Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG-75202 in Myeloid Malignancies
NCT07619287Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Jun 2026
- Primary completion
- Sep 2028
- Countries
- 3
01
Overview
Phase 1, open-label trial of BG-75202 in Myeloid malignancy (3 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) at 18 months, Recommended Dose for Expansion of BG-75202 at 18 months and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
BG-75202
03
Conditions
Myeloid malignancy
Beyond the preview
Go deeper on NCT07619287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619287.